Brooklyn FI LLC Boosts Position in Johnson & Johnson (NYSE:JNJ)

Brooklyn FI LLC lifted its holdings in Johnson & Johnson (NYSE:JNJ) by 6,239.7% during the fourth quarter, Holdings Channel reports. The fund owned 127,682 shares of the company’s stock after buying an additional 125,668 shares during the quarter. Brooklyn FI LLC’s holdings in Johnson & Johnson were worth $19,795,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also recently made changes to their positions in JNJ. Vinva Investment Management Ltd lifted its holdings in shares of Johnson & Johnson by 6.8% in the 3rd quarter. Vinva Investment Management Ltd now owns 111,448 shares of the company’s stock valued at $17,988,000 after buying an additional 7,110 shares during the period. Financial Counselors Inc. lifted its holdings in Johnson & Johnson by 5.3% in the third quarter. Financial Counselors Inc. now owns 185,093 shares of the company’s stock valued at $29,996,000 after acquiring an additional 9,309 shares during the period. Oregon Pacific Wealth Management LLC purchased a new stake in Johnson & Johnson in the 4th quarter worth approximately $949,000. Horan Securities Inc. grew its stake in shares of Johnson & Johnson by 1.3% during the 4th quarter. Horan Securities Inc. now owns 7,178 shares of the company’s stock worth $1,038,000 after purchasing an additional 90 shares during the period. Finally, Strategic Financial Concepts LLC increased its holdings in shares of Johnson & Johnson by 57.9% during the 4th quarter. Strategic Financial Concepts LLC now owns 3,467 shares of the company’s stock valued at $501,000 after purchasing an additional 1,271 shares in the last quarter. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Insider Buying and Selling at Johnson & Johnson

In other news, EVP Timothy Schmid sold 403 shares of the business’s stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $156.15, for a total value of $62,928.45. Following the sale, the executive vice president now directly owns 15,098 shares of the company’s stock, valued at approximately $2,357,552.70. The trade was a 2.60 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP Robert J. Decker sold 6,999 shares of the stock in a transaction that occurred on Tuesday, February 25th. The stock was sold at an average price of $165.88, for a total transaction of $1,160,994.12. Following the transaction, the vice president now directly owns 21,001 shares of the company’s stock, valued at $3,483,645.88. The trade was a 25.00 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 0.16% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts recently commented on the stock. Barclays raised their price target on shares of Johnson & Johnson from $159.00 to $166.00 and gave the company an “equal weight” rating in a research report on Tuesday, January 28th. Wells Fargo & Company cut their price target on Johnson & Johnson from $166.00 to $152.00 and set an “equal weight” rating for the company in a research note on Thursday, January 23rd. Guggenheim reissued a “neutral” rating on shares of Johnson & Johnson in a report on Monday, March 10th. Stifel Nicolaus reduced their target price on Johnson & Johnson from $170.00 to $155.00 and set a “hold” rating for the company in a research note on Thursday, January 23rd. Finally, Royal Bank of Canada reissued an “outperform” rating and issued a $181.00 price target on shares of Johnson & Johnson in a research note on Wednesday, February 19th. Nine analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $171.33.

Johnson & Johnson Stock Up 0.9 %

Shares of NYSE:JNJ opened at $164.24 on Wednesday. Johnson & Johnson has a 52-week low of $140.68 and a 52-week high of $169.99. The company has a quick ratio of 0.86, a current ratio of 1.11 and a debt-to-equity ratio of 0.43. The business has a fifty day moving average of $155.73 and a two-hundred day moving average of $156.25. The stock has a market cap of $395.80 billion, a P/E ratio of 24.70, a PEG ratio of 2.56 and a beta of 0.47.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Wednesday, January 22nd. The company reported $2.04 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.99 by $0.05. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. The firm had revenue of $22.52 billion during the quarter, compared to analysts’ expectations of $22.44 billion. During the same period last year, the business earned $2.29 earnings per share. Johnson & Johnson’s revenue was up 5.3% compared to the same quarter last year. On average, research analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Tuesday, March 4th. Shareholders of record on Tuesday, February 18th were paid a dividend of $1.24 per share. The ex-dividend date of this dividend was Tuesday, February 18th. This represents a $4.96 annualized dividend and a yield of 3.02%. Johnson & Johnson’s dividend payout ratio (DPR) is 74.59%.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.